galantamine has been researched along with Cortical Lewy Body Disease in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (93.75) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shoji, M | 1 |
| Graham, K; Josif, S | 1 |
| Kaufer, DI | 2 |
| Bednarczyk, EM; Edwards, KR; Farlow, M; Hershey, L; Johnson, S; Lichter, D; Wray, L | 1 |
| Levin, OS | 1 |
| Bhanji, NH; Gauthier, S | 1 |
| Cummings, JL; Ringman, JM | 1 |
| Johannsen, P | 1 |
| Bhasin, M; Edwards, K; McKeith, I; Rowan, E | 1 |
| Edwards, K; Farlow, M; Hake, A; Hershey, L; Johnson, S; Lichter, D; Pasquier, F; Royall, D | 1 |
| Ballard, CG; Chalmers, KA; Love, S; McKeith, IG; O'Brien, JT; Perry, EK; Todd, C; Wilcock, G | 1 |
| Gallini, A; Montastruc, JL; Salandini, AM; Sommet, A; Veyssière, P | 1 |
| Anghelescu, I; Heuser, I | 1 |
| Landmark, K; Reikvam, A | 1 |
6 review(s) available for galantamine and Cortical Lewy Body Disease
| Article | Year |
|---|---|
[Programs for continuing medical education: a session; 3. Dementia: diagnosis and therapy].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibitors; Cognitive Dysfunction; Dementia; Disease Progression; Donepezil; Education, Medical, Continuing; Galantamine; Humans; Indans; Lewy Body Disease; Nootropic Agents; Peptide Fragments; Phenylcarbamates; Piperidines; Positron-Emission Tomography; Reference Standards; Rivastigmine; tau Proteins; Tomography, Emission-Computed, Single-Photon | 2014 |
Diagnosis and treatment of dementia with Lewy bodies.
Topics: Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Nootropic Agents; Phenylcarbamates; Piperidines; Prognosis; Rivastigmine; Tacrine | 2008 |
Current and emerging pharmacological treatment options for dementia.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2006 |
[Medical treatment of Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Dementia, Vascular; Disease Progression; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Lewy Body Disease; Memantine; Nootropic Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2006 |
[Acetylcholinesterase inhibitors for dementia--an update].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Time Factors | 2007 |
[Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Dementia, Vascular; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Lewy Body Disease; Phenylcarbamates; Piperidines; Rivastigmine; Time Factors; Treatment Outcome | 2008 |
1 trial(s) available for galantamine and Cortical Lewy Body Disease
| Article | Year |
|---|---|
Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.
Topics: Aged; Aged, 80 and over; Behavioral Symptoms; Cholinesterase Inhibitors; Dementia; Dose-Response Relationship, Drug; Female; Galantamine; Hallucinations; Humans; Lewy Body Disease; Male; Mental Status Schedule; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinsonian Disorders; Treatment Outcome | 2007 |
9 other study(ies) available for galantamine and Cortical Lewy Body Disease
| Article | Year |
|---|---|
Pharmacologic treatment expectations in the management of dementia with Lewy bodies.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Brain; Carbamates; Cholinesterase Inhibitors; Diagnosis, Differential; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2004 |
Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Galantamine; Humans; Lewy Body Disease; Male; Mental Status Schedule; Middle Aged; Neurologic Examination; Neuropsychological Tests; Nootropic Agents; Treatment Outcome; Uridine | 2004 |
A case study in the treatment of dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Carbamates; Cognition Disorders; Donepezil; Drug Resistance; Female; Galantamine; Hallucinations; Humans; Indans; Lewy Body Disease; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Psychomotor Agitation; Rivastigmine; Social Behavior | 2004 |
[Reminyl efficacy in dementia with Levi bodies].
Topics: Aged; Cholinesterase Inhibitors; Data Interpretation, Statistical; Galantamine; Humans; Lewy Body Disease; Middle Aged; Nootropic Agents; Psychometrics; Time Factors; Treatment Outcome | 2005 |
Emergent complications following donepezil switchover to galantamine in three cases of dementia with Lewy bodies.
Topics: Aged; Cholinesterase Inhibitors; Disease Progression; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Male; Mental Status Schedule; Neuropsychological Tests; Piperidines | 2005 |
Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis.
Topics: Aged; Analysis of Variance; Cholinesterase Inhibitors; Clinical Trials as Topic; Data Interpretation, Statistical; Donepezil; Female; Galantamine; Humans; Indans; Lewy Body Disease; Male; Neuropsychological Tests; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Rivastigmine; Treatment Outcome | 2007 |
Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Amyloid beta-Peptides; Autopsy; Cerebral Cortex; Cholinesterase Inhibitors; Clinical Trials as Topic; Cohort Studies; Donepezil; Drug Evaluation; Female; Galantamine; Humans; Indans; Lewy Body Disease; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Piperidines; Prospective Studies; Rivastigmine; Tacrine; tau Proteins; Tauopathies | 2007 |
Weight-loss associated with anti-dementia drugs in a patient with Parkinson's disease.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Anorexia; Antiparkinson Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Galantamine; Humans; Lewy Body Disease; Memantine; Mental Status Schedule; Nausea; Nootropic Agents; Parkinson Disease; Vomiting; Weight Loss | 2007 |
Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Dystonia; France; Galantamine; Humans; Indans; Lewy Body Disease; Parkinson Disease; Phenylcarbamates; Piperidines; Tremor | 2007 |